Data analysis method in mycobacterium tuberculosis detection

Through the combination of mPCR and NGS technology, primer sets covering 17 drug-resistant genes of 16 therapeutic drugs are designed, which can achieve rapid detection of Mycobacterium tuberculosis, and solve the problems of long detection cycles and cumbersome drug resistance diagnosis in the existing technology. , improves the efficiency and accuracy of detection and prevents sample contamination.

CN118910298APending Publication Date: 2024-11-08DINFECTOME +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411140515.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-21
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing M. tuberculosis detection method has a long cycle and cannot provide real-time and effective information, resulting in a prolonged treatment time. The existing drug resistance diagnosis methods are cumbersome and time-consuming, making it difficult to quickly achieve 17 of the 16 therapeutic drugs for M. tuberculosis. Simultaneous detection of drug-resistant genes.

Method used

Using multiplex PCR (mPCR) combined with nucleic acid fragmentation technology and secondary sequencing (NGS), primer sets covering 17 drug-resistant genes of 16 therapeutic drugs were designed, amplified by mPCR and fragmented, and using SE50 sequencing strategy to quickly Detect mutations in drug resistance sites and prevent sample contamination through specific linker sequences.

Benefits of technology

The rapid detection of 17 drug-resistant genes of 16 therapeutic drugs of Mycobacterium tuberculosis has been achieved, which reduces the detection time and cost, improves the conservatism and accuracy of the detection, and can effectively screen SNP sites and be in the same batch. Sample contamination is distinguished in the sub-sample.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910298A_ABST
    Figure CN118910298A_ABST
Patent Text Reader

Abstract

The invention relates to a data analysis method in mycobacterium tuberculosis detection, and belongs to the technical field of gene detection. According to the method, the specific tag sequence is designed and added into the linker, and the linker sequence does not exist in mycobacterium tuberculosis, so that pollution analysis on other project samples in the same batch can be realized, and the linker sequence has no influence on a detection result.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a data analysis method in mycobacterium tuberculosis detection, belonging to the technical field of gene detection. Background Art

[0002] Tuberculosis (TB) and Mycobacterium tuberculosis (Mtb): Tuberculosis is a common and fatal chronic infectious disease. Human tuberculosis is mainly caused by Mycobacterium tuberculosis complex (MTBC). TB in the latent stage does not show any symptoms, but once it develops into an active disease (about 10%), it becomes extremely dangerous and contagious. If it is not treated promptly and effectively, the mortality rate of active tuberculosis is as high as 66%.

[0003] Tuberculosis resistance: Due to the special structure and chemical composition of the Mtb cell wall, effective tuberculosis treatment is difficult and patients need to take medication for a long time. The main method of treating active tuberculosis is to use a combination of multiple antibiotics to reduce the development of antibiotic resistance. Even so, factors such as inadequate treatment, lack of compliance with treatment plans, and use of inferior drugs may still lead to the development of secondary resistance during treatment.

[0004] Tuberculosis has a high mortality rate, and early, rapid and effective etiological diagnosis is extremely important for the immediate treatment of tuberculosis and the reduction of mortality and sequelae. Sanger sequencing detection and the current gold standard for diagnosing tuberculosis resistance, "culture drug sensitivity test", have the defects of long cycles, cannot provide real-time and effective information, and are likely to delay treatment time; NGS methods using probes are cumbersome and relatively time-consuming. Summary of the invention

[0005] The present invention provides a detection method that can simultaneously cover 17 drug resistance genes of 16 therapeutic drugs for Mycobacterium tuberculosis. In this method, the amplified fragment of the target gene is first obtained by the mPCR method, and then the amplicon is fragmented and sequenced by NGS, which can quickly detect the mutation of the above key drug resistance sites, and has the advantage of good conservatism, and can effectively amplify and detect the currently known Mycobacterium tuberculosis drug resistance genes. The technical solution is:

[0006] An mPCR primer set for detecting drug resistance sites of Mycobacterium tuberculosis, comprising a primer pair with nucleotide sequences as shown in SEQ ID NO.1-36.

[0007] Also included are primer pairs whose nucleotide sequences are shown as SEQ ID NO.37-42.

[0008] A kit comprising the above primer set.

[0009] The kit also includes nucleic acid fragmentation enzyme.

[0010] Application of the above mPCR primer set in the preparation of a kit for detecting drug-resistant gene mutation of Mycobacterium tuberculosis.

[0011] A method for detecting drug-resistant gene mutations of Mycobacterium tuberculosis comprises the following steps:

[0012] Step 1, after removing the host from the sample, lyse it and then extract the nucleic acid;

[0013] Step 2, performing a multiplex PCR reaction using an mPCR primer set to obtain amplicons;

[0014] Step 3, after the amplicon is subjected to enzyme digestion and fragmentation treatment, the ends are repaired and A is added, and the adapter is connected;

[0015] Step 4: perform high-throughput sequencing.

[0016] In the step 3, a fragmentation enzyme is used in the fragmentation treatment to break the mPCR amplification product into a length of about 50-300 bp.

[0017] In step 4, the sequencing is performed using the SE50 method.

[0018] In step 4, the BGI200 sequencing platform is used, and the linker sequences are shown in SEQ ID NOs. 43, 47, 48, and 46.

[0019] The step 4 also includes analyzing the sample data of other test items in the same batch. If Mycobacterium tuberculosis is found in other items and the above-mentioned TGCTTA tag sequence is not present, it is considered that the structural mycobacteria in these other items exist by themselves and are not caused by sample contamination.

[0020] The sample is selected from alveolar lavage fluid, sputum, pleural effusion, swabs (oropharyngeal swabs, cheek swabs, etc.), blood sediment, pus, bile, renal lavage fluid, pericardial effusion, joint fluid, cerebrospinal fluid, whole blood, drainage fluid, puncture fluid, fresh tissue, and feces.

[0021] Beneficial Effects

[0022] The advantages of the detection method of the present invention include: 1) It covers a wide range of drug-resistant drug types and mutation sites, and can simultaneously and rapidly detect 17 tuberculosis-resistant mutation-related genes corresponding to 16 tuberculosis treatment drugs. 2) This method uses mPCR, amplicon fragmentation and NGS sequencing, which can quickly detect related site regions. 3) This method has better conservatism. By analyzing a large number of samples and screening out the SNP sites therein, it can effectively amplify and detect the currently reported Mycobacterium tuberculosis. 4) In this method, a specific tag sequence is designed and added to the connector. The connector sequence does not exist in Mycobacterium tuberculosis, so contamination analysis of samples from other projects in the same batch can be realized, and the connector sequence has no effect on the test results. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 It is the sequencing depth value of each base in the final fragmentation product of the entire amplicon.

[0024] Figure 2 is the sequencing depth value of each coverage site.

[0025] Figure 3 It is the quality control test result of the fragments before and after fragmentation processing.

[0026] Figure 4 This is the sequencing depth result when 21 pairs of primers were tested. DETAILED DESCRIPTION

[0027] The development goal of the present invention is to cover 16 tuberculosis treatment drugs, including 4 first-line drugs commonly used in clinical practice (isoniazid, rifampicin, ethambutol, pyrazinamide) and 12 second-line drugs (fluoroquinolones, kanamycin, amikacin, capreomycin, streptomycin, ethionamide, prothionamide, cycloserine, clofazimine, linezolid, para-aminosalicylic acid, bedaquinine). 17 tuberculosis resistance mutation-related genes (rpoB, inhA, katG, fabG1, pncA, embB, gyrA, gyrB, rrs, eis, rpsL, folC, thyA, alr, rplC, rrl, rv0678) are involved.

[0028] The process of this method:

[0029] 1. Design of mPCR primer set

[0030] This patent is based on the following considerations when designing mPCR primers:

[0031] By consulting relevant literature, we identified 17 Mycobacterium tuberculosis resistance-related genes including rpoB, inhA, katG, fabG1, pncA, embB, gyrA, gyrB, rrs, eis, rpsL, folC, thyA, alr, rv0678, rplC, and rrl. The core difficulty of primer design is that it is necessary to consider the conservation, specificity, GC content, TM value, hairpin structure, primer length, non-specific amplification of primer sets, and primer dimers of single primers at the same time.

[0032] Table 1. Table of the first group of tuberculosis drug resistance gene mutation detection sites detected in the present invention

[0033]

[0034]

[0035]

[0036]

[0037]

[0038] First, the original bases of the proposed mutation sites were checked for correctness based on the Mtb reference genome H37Rv. Second, all mutation sites were extended 500 bp upstream and downstream, and the overlap regions were merged to obtain a total of 21 initial template sequences of about 1000 bp in length (18 amplified regions originally containing mutation sites, and 3 other drug resistance gene site regions were added on this basis).

[0039] Table 2. Table of the second group of additional tuberculosis drug-resistant gene mutation detection sites detected in the present invention

[0040] drug Mutant gene cDNA mutation site Clofazimine Rv0678 350T>G Clofazimine Rv0678 403C>G Clofazimine Rv0678 407T>C Clofazimine Rv0678 437T>C Clofazimine Rv0678 466C>T Bedaquiline Rv0678 65A>T Bedaquiline Rv0678 97A>G Bedaquiline Rv0678 189C>A Bedaquiline Rv0678 198delG Bedaquiline Rv0678 214C>T Bedaquiline Rv0678 257C>T Bedaquiline Rv0678 323T>C Bedaquiline Rv0678 326G>C Bedaquiline Rv0678 350T>G Bedaquiline Rv0678 403C>G Bedaquiline Rv0678 407T>C Bedaquiline Rv0678 437T>C Cycloserine alr 65C>T Cycloserine alr 338T>G Cycloserine alr 1028T>C Cycloserine alr 1030C>T Cycloserine alr 1162T>G

[0041] Subsequently, the initial template sequence was aligned with 1408 complete Mtb genome sequences downloaded from GeneBank using blastn software (identity>90) (tuberculosis genome selection conditions: genome integrity>0.99, genome contamination ratio<0.01), and finally 1408×21 alignment sequences were obtained. Fastq data was generated for the alignment sequence using slide 1 and windows 150 parameters, and then BWA-MEM was used to align the 21 template sequences to obtain mutation information on the template sequences. Then the primer design template sequence was confirmed, and the region with mutations in the mask template sequence was masked to obtain the final template sequence for primer design. Then Primer3 was used to generate candidate primers for each sequence, forming a primer set for subsequent primer screening, and finally 105 pairs of candidate primers were generated. The best primers were selected from each sequence according to the design parameters, and finally 21 pairs of candidate primers were selected. At the same time, all primers were required to pass the conservation, specificity and clinical detection rate evaluation and cover all detection sites.

[0042] Table 3 Genomic location information of 21 subsequent amplification templates

[0043] Amplicon name Genome start position Genomic end position ikB 6154 7153 yrA 6988 7987 rpoB 760730 761729 Rv0678 778615 779614 rPv 781237 782236 R 800697 801696 rrs-1 1471741 1472740 rrs-2 1472864 1473863 rrl 1475830 1476829 fabG1(mabA) 1673050 1674049 iA 1673533 1674532 katG 2154460 2155459 pncA 2288483 2289482 eis 2715014 2716013 fOI 2746674 2747673 thyA-1 3073092 3074091 thyA-2 3073716 3074715 alr-1 3839886 3840885 alr-2 3840605 3841604 embB-1 4247047 4248046 embB-2 4247602 4248601

[0044] Table 4 21 pairs of primer sequences

[0045]

[0046] Primer design parameters are as follows:

[0047] 1. The GC content of the primer sequence is between 40-60, the length is between 18-25, and it does not form a hairpin structure;

[0048] 2. Primer sequence conservation: The similarity of the compared genome sequences is 100%;

[0049] 3. Primer sequence specificity: The similarity of primer sequences to non-target species should be less than 90%;

[0050] 4. Primer dimer: The number of consecutive complementary pairs between primers is less than 4;

[0051] 5. Non-specific amplification: The length of potential non-specific amplification template should be greater than >1000.

[0052] There are two main technical difficulties in primer design. The first is that there are many different strains of Mycobacterium tuberculosis, and different strains have different polymorphic sites. The presence of these sites will lead to the inability to achieve effective amplification and detection on specific strains. Therefore, it is necessary to consider how to design primers that can have 100% similarity in all strain sequences. The second is to evaluate primer dimers and non-specific amplification between primer groups.

[0053] 1. Primer conservation. Tuberculosis lacks a sequence mutation database. Therefore, we downloaded thousands of Mycobacterium tuberculosis genomes from GeneBank and simulated 10×fastq data based on them. Then, we compared the sequences with the reference genome sequence of tuberculosis (Mycobacterium tuberculosis H37Rv) and identified variations. The purpose was to establish a polymorphism database for tuberculosis sequences. By excluding the corresponding polymorphic sites, 100% conservative regions were obtained. For candidate amplification template sequences, the sites with mutation frequencies greater than 0.001 (202 SNP sites) were masked according to the self-built tuberculosis polymorphism database, and then the masked sequences were used for primer design. For example, there is a SNP site at position 3073868 of the thyA gene (g.3073868T>C, MAF is 0.23), and the primer sequence needs to avoid these SNP site regions.

[0054] Table 5 Distribution of polymorphic sites (MAF>=0.01) in candidate template sequences

[0055]

[0056]

[0057] 2. Primer set evaluation. Primers may form dimers and perform non-specific amplification. Therefore, we calculate the number of complementary bases between primers and the length of the potential amplified fragment, and then score the primers based on the results. We remove low-quality primers with scores exceeding the threshold in a cycle until all primer scores are below the threshold and output the final primer set.

[0058] Among the primer sets designed above, the first 18 pairs can detect the drug-resistant sites of most selected Mycobacterium tuberculosis. These 18 pairs of primers can be used as an mPCR primer set for detection individually. In addition, the 21 pairs of primers after incorporating 3 supplementary primers can also be used as an mPCR primer set for detection, so as to achieve the purpose of covering more drugs and drug-resistant related genes.

[0059] Therefore, based on the large amount of data query and screening work in this patent, combined with the corresponding primer design method, thousands of Mtb strain genomes from all over the world were screened and analyzed simultaneously, and targets with good detection value were obtained, which enabled the mPCR primers to have good amplification capabilities when facing Mtb from various sources.

[0060] After the amplification is completed, the amplicon is also fragmented. The amplicon fragmentation technology is introduced for the first time in the detection of tuberculosis drug-resistant mutations. The mPCR is combined with the SE50 sequencing strategy. Compared with similar products, the sequencing time is shortened, the cost is reduced, and the sequencing depth of each site is more uniform. The fragmentation enzyme used for enzyme cutting and interruption comes from the fragmentation enzyme Smearase in the BGI library construction kit with the product number 13509ES96 produced by Yisheng Biotechnology (Shanghai) Co., Ltd. After enzyme cutting, the DNA fragments of about 440bp in length (similar to the length of the mPCR amplification product of 21 pairs of primers) can be almost completely interrupted to a length of about 50-300bp by controlling the time to meet the needs of the SE50 sequencing strategy. This sequencing method can only measure the 50bp length sequence at one end of the library fragment, so there needs to be enough sequences with a length close to and not less than 50bp, and it is required to be able to uniformly cover the entire amplification product area to achieve full sequence sequencing of the amplification product. On the contrary, if the enzyme is not cut, the entire sequence of the amplification product cannot be known, and sequencing comparison cannot be performed.

[0061] In addition, in the process of library construction, the present invention designs a special Mtb adapter suitable for the BGI sequencing platform, which can effectively prevent the contamination of samples in the same batch. Usually, in one sequencing, samples from other projects may be brought into the Mycobacterium tuberculosis sample due to contamination, resulting in errors. Therefore, if a specific tag can be added to the Mtb sample adapter, other samples can be effectively distinguished from Mtb samples.

[0062] Table 6

[0063]

[0064] The table above shows the requirements of the Primer sequence for the BGI200 sequencing platform. These sequences are required to be present in order at both ends of the library in order to distinguish the regions that need to be read. The forward and reverse Primers have a 7nt-long complementary sequence. In the present invention, a complementary sequence is added to the 3' end of the forward and reverse Primers. The forward and reverse sequences of the special adapter are:

[0065] 5'-TTGTTCTTCCTAAGCAACTCCTTGGCTCACAGAACGACATGGCTACGAT CCGACT T GCTTA T-3' (SEQ ID NO.47)

[0066] 5'-( A )TAAGCA AGTCGG AGGCCAAGCGGTCTTAGGAAGACAATCAG-3'(SEQ ID NO.48)

[0067] The underlined characters are the original complementary sequences, (A) are the complementary sequences added to the 3' end of the target sequence by Smearase enzyme after end repair (not included in the adapter), and the italic characters are the complementary sequences added later.

[0068] As a filtering "marker" for bioinformatics analysis. This marker has four screening principles: the insertion sequence cannot be too long, affecting the connection of the adapter, ≤6nt; the insertion sequence cannot appear in the amplicon region, otherwise normal mNGS reads may be judged as contamination (when the adapter length is shorter, its specificity will decrease, resulting in an increased possibility of being identical to the region in the amplicon. Therefore, how to ensure that it is not identical to the amplicon region under the condition of a shorter label length also has corresponding difficulties); base balance; cannot affect the binding of the 3' end T of the sequencing primer. Comparison of library construction results shows that special adapters have almost no effect on the quality of library construction, nor will they cause excessive nonspecific amplification.

[0069] After the above screening, the length of the obtained tag is 6nt, and the sequence of the tag is TGCTTA. Since the tag sequence does not exist in the Mycobacterium tuberculosis gene, when testing other samples of the same batch, if Mycobacterium tuberculosis is found in other items and the above tag is not present, it is considered that the structural mycobacteria in these other items exist by themselves and are not caused by sample contamination.

[0070] Example 1 Sample detection process

[0071] 1. Extraction process (mainly including host removal process and homogenization process, host removal process includes host removal pre-treatment, homogenization lysis and magnetic bead extraction, and homogenization process includes homogenization lysis and magnetic bead extraction); the method in the present invention supports the submission of various types of samples: Mycobacterium tuberculosis enters the blood from the infected site and can spread throughout the body, and almost all parts have the opportunity to be infected. This detection method supports the submission of a variety of samples including the following samples: alveolar lavage fluid, sputum, pleural effusion, swabs (oropharyngeal swabs, cheek swabs, etc.), blood sediment, pus, bile, kidney lavage fluid, pericardial effusion, joint fluid, cerebrospinal fluid, whole blood, drainage fluid, puncture fluid, fresh tissue, feces. The samples in the following embodiments are derived from alveolar lavage fluid and sputum.

[0072] 1.1 Pre-host treatment

[0073] 1.1.1. Sampling: Take a certain volume of sample according to the sample status and put it into a 2.0mL centrifuge tube, check the sample number and mark it. 1.1.2. Centrifugation: Put the sample into a centrifuge, centrifuge at 10000g for 5 minutes, discard the supernatant and keep the precipitate, and keep 200μL at the bottom without precipitation.

[0074] 1.1.3. Lyse human cells: Add PBS to 1 mL in a centrifuge tube to resuspend the pellet, then add 500 μL of host-free lysis buffer, mix well, place in a vortexer, and incubate at 2000 rpm at room temperature for 5 minutes.

[0075] 1.1.4. Collect microbial cells: centrifuge at room temperature for 3 minutes at 16000g, discard the supernatant and keep the precipitate, keep 200μL without precipitate, add universal nuclease and nuclease buffer, and then incubate in a metal bath at 37℃ for 5 minutes.

[0076] 1.1.5. Add digestive enzymes and internal reference: Add 20 μL proteinase K, vortex to mix, and then place in a metal bath and incubate at 56°C for 10 minutes. After the incubation, add 10 μL of 10 cells / μL internal reference diluent, vortex to mix, and centrifuge.

[0077] 1.2 Homogenization

[0078] 1.2.1. Homogenization: Add 1 mL of PBS to the sample and transfer all the liquid to a Lysing Matrix E tube. Place the tube in a cell mechanical lyser for mechanical lysis. Centrifuge at 16,000 g for 10 min and transfer the supernatant to a 5 mL centrifuge tube.

[0079] 1.3 Magnetic bead extraction

[0080] 1.3.1 Add proteinase K and lysis buffer, mix well and incubate in a 60℃ water bath or metal bath for 10 min.

[0081] 1.3.2 Nucleic Acid: Add the pre-washed magnetic beads into a 5 mL centrifuge tube, place it on a multi-tube vortex mixer, vortex and resuspend, and incubate at room temperature for 10 min.

[0082] 1.3.3 Purify nucleic acid: Add washing solution 1, washing solution 2 and anhydrous ethanol to a 5 mL centrifuge tube for nucleic acid purification.

[0083] Dry transfer nucleic acid: Place the purified nucleic acid in a metal bath at 56°C with the lid open to dry, then add enzyme-free water to elute the transferred nucleic acid. 1.3.4 Quantitative transfer library construction process: Perform Qubit quantification on the nucleic acid.

[0084] 2. Tuberculosis resistance mPCR process

[0085] 2.1 Confirmation of input volume: The sample input volume is 10 ng. According to the DNA concentration, take the corresponding volume of DNA and add water to 12 μL. If it is less than 10 ng, take 12 μL directly.

[0086] 2.2 Preparation of reaction mix: Add primer working solution II (3 μL) and 2×Hieff HGMultiplex PCR Master Mix (15μL).

[0087] 2.3 Multiplex PCR reaction: Add the reaction mix to 12 μL of sample on ice, pipette to mix, and perform multiplex PCR reaction.

[0088] Table 7

[0089]

[0090] In conducting multiple groups of experiments, different groups were used in this patent for mPCR amplification and subsequent sequencing experiments, including: Group 1: mPCR reaction was performed using primer pairs targeting 18 tuberculosis resistance sites;

[0091] Group 2: Based on the first group, three additional pairs of primers were included in the mPCR reaction;

[0092] 2.4 0.7× magnetic bead purification: Add 21 μL of purified magnetic beads to the multiple PCR products, pipette to mix well and let stand at room temperature, then place on a magnetic rack for magnetic absorption and discard the supernatant. Wash twice with 200 μL of 80% ethanol; remove all residual ethanol, dry the magnetic rack and add 30 μL of enzyme-free water for elution.

[0093] 2.4 mPCR product quantification: Transfer 28 μL of the eluted mPCR reaction product to a new centrifuge tube, take 1 μL for Qubit quantification, and then transfer to the DNA library construction process.

[0094] 3. DNA library construction process

[0095] 3.1. Confirmation of input volume: The input volume for library construction is 10 ng. According to the concentration of mPCR product, take the corresponding volume of DNA and add water to 25 μL. If the concentration is lower than 10 ng, take 25 μL.

[0096] 3.2. Enzyme digestion, end repair and A addition: Add 5μL Smearase mix to 25μL sample on ice, pipette to mix, and perform enzyme digestion, end repair and A addition reaction.

[0097] 3.3. Adapter ligation (In the test of the first set of primers for mPCR in Section 2.3 above, a comparative test using universal adapters and special labeled adapters was added here): Prepare ligation Mix (including Ligation Enhancer + Fast T4DNA Ligase + adapters), add ligation Mix to the sample after the reaction in step 3.2 on ice, mix by pipetting and then carry out ligation reaction.

[0098] 3.4.0.8× magnetic bead purification: Add 40μL of purified magnetic beads to the ligated product, pipette and mix well, let stand at room temperature, place on a magnetic rack, and discard the supernatant; wash twice with 200μL of 80% ethanol; remove all residual ethanol, dry on a magnetic rack, and add 25μL of PCR Mix for elution.

[0099] 3.5. on Beads PCR amplification: pipette and mix the sample in step 4, then run the PCR reaction program and amplify for 7 cycles.

[0100] 3.6.0.7× magnetic bead purification: add 17.5μL purified magnetic beads to the amplified product, pipette to mix, let stand at room temperature for 3 min, place on a magnetic stand for 1 min, and discard the supernatant; wash with 200μL 80% ethanol for 30s, discard the supernatant, and wash twice in total; remove all residual ethanol and dry on a magnetic stand for 2 min; add 24μL enzyme-free water for elution, pipette to mix, let stand at room temperature for 3 min, place on a magnetic stand for 1 min, and transfer 20μL of the library.

[0101] 3.7 Concentration determination: Perform Qubit quantification on the library and dilute it according to the concentration requirements of the machine (below 1 ng / μL).

[0102] 4. Library loading (MGI 200 sequencer, SE50, 1M sequencing throughput)

[0103] 5. Bioinformatics analysis process

[0104] In addition to the feedback of basic quality control data such as Raw_Reads, HQ_Reads, GC ratio, Q30%, and Dup%, the bioinformatics analysis process also requires the detection target to be compared and screened out for Mycobacterium tuberculosis Reads, host Reads (normally human Reads), and other pathogen Reads in HQ_Reads, and their proportions in HQ_Reads are calculated to evaluate the effect of mPCR and the quality of library construction: Mtb-positive samples should have a higher Mtb ratio, while Mtb-negative samples should have a larger proportion of host Reads and other pathogen Reads.

[0105] This process also includes the analysis of depth area to measure the quality of the entire process of sample extraction, library construction and computer processing: Mtb positive samples should meet the following three conditions at the same time:

[0106] 1. Obtain at least 3 of the 21 amplicons;

[0107] 2. The sequencing depth of each site within the range of all amplicon sequences should not be less than 30.

[0108] Otherwise, it is judged as a low-quality sample (possibly due to non-compliant process operations or sample contamination by Mtb).

[0109] The amplicon DNA fragments after shearing were subjected to 2100 quality inspection, such as Figure 3 As shown, region A is not interrupted: it can be seen that there are more fragments around 377 and 446 bp, region B is interrupted for 5 minutes: fragments below 300 bp are obviously present, and the proportion of large fragments of 370-450 bp decreases, region C is interrupted for 8 minutes: the proportion of fragments less than 200 bp increases, and region D is interrupted for 10 minutes: large fragments are basically all interrupted. The results show that compared with before interruption, the fragments around 440 bp are significantly reduced, and the interruption is basically completed at 10 minutes. Figure 1 The final sequencing depth values ​​of each base of the fragmented products of the entire amplicon are displayed. Although the uniformity did not fully meet the experimental expectations, the library obtained sufficient sequencing depth values ​​for all sites on the entire amplicon fragment. The same data verification was performed on all amplicons and the required sequencing depth could be achieved.

[0110] Table 8

[0111]

[0112] The table above compares the data of four samples (No. 4 is a Mycobacterium tuberculosis negative sample) tested with 18 pairs of primers and using two types of adapters for library construction. It can be seen that the special adapter has no obvious effect on the quality control data.

[0113] Taking the special joint test experiment as an example, the results are as follows:

[0114] Table 9

[0115]

[0116] The above table shows the proportion of each category of reads in the sequencing results. It can be seen that the use of special connectors does not affect the reading, detection and classification of each type of reads.

[0117] Figure 2 The overall coverage of the special adapter shows that the sequencing depth values ​​of each site are similar to those of the universal adapter (the vertical axis is the log of the sequencing depth). 10, different color areas represent different amplicons); sample 4 is contaminated with a small amount of Mtb amplicon. The following table shows the drug-resistant mutations reported for the four samples. It can be seen that replacing the adapter does not affect the detection of drug-resistant mutations, and the depth of the mutation site decreases by 20% with the amount of sequencing data, that is, the relative sequencing abundance value remains unchanged.

[0118] Table 10

[0119]

[0120] *Note: The contents in brackets are (sequencing depth of the site, relative sequencing abundance value of the mutant base at the site)

[0121] Further, 21 pairs of primers were used for detection, and the remaining detection parameters and conditions were consistent with those in the embodiment. Samples 8, 9, 16, and 24 in the table below are negative samples, and sample 23 is NTC. The remaining samples are clinical samples with different concentrations of Mycobacterium tuberculosis sequences (the arrangement is independent of the sequence concentration). Figure 4 21 amplicon regions of 24 samples are displayed, with the ordinate being the sequencing depth value (log10), the blue background being the negative sample, and the gray background being the NTC. The three red lines show the sequencing depth values ​​of 1k×, 100×, and 10×, respectively. The black dotted line is the 30× sequencing depth threshold required for detection. It can be seen that positive samples with normal mPCR amplification can obtain a relatively uniform sequencing depth distribution that is far higher than the 30× threshold; although some Mtb sequences are detected in negative samples and NTC, they can be filtered by the positive judgment criteria. The specific test results are as follows:

[0122] Table 11

[0123]

[0124]

[0125] Table 12

[0126]

[0127] The table above compares the data of the library construction when 24 samples were tested using 21 pairs of primers. It can be seen that the amount of nucleic acid and data of most samples are in line with expectations, and HQ_Reads_Pct is above 90% (the amount of mPCR template input in sample 4 is less than the specified 10ng standard, so there is difficulty in mPCR amplification). The sequencing depth of each amplicon in the positive sample meets the analysis requirements and does have a high sequence repetition rate.

[0128] Table 13

[0129]

[0130]

[0131] The table above shows the proportion of reads in each category in the sequencing results. It can be seen that the positive samples obviously have a high level of Mtb sequences.

[0132] Table 14

[0133]

[0134]

[0135] The above table shows the detection of drug-resistant mutations in 24 samples. This patent can detect most of the identified drug-resistant mutation sequences, and is consistent with the results of drug sensitivity tests, confirming that this method can effectively detect drug-resistant sites.

Claims

1. A method for analyzing data of other test item samples of the same batch in the detection of drug-resistant gene mutation of Mycobacterium tuberculosis, characterized in that: The steps include: The sample data of other test items in the same batch are analyzed. If Mycobacterium tuberculosis is found in other items and the TGCTTA tag sequence is not present, it is considered that the structural mycobacteria in these other items exist by themselves and are not caused by sample contamination.

2. The sample data analysis method according to claim 1, characterized in that: The detection of drug-resistant gene mutations in Mycobacterium tuberculosis includes the following steps: Step 1, after removing the host from the sample, lyse it and then extract the nucleic acid; Step 2, performing a multiplex PCR reaction using an mPCR primer set to obtain amplicons; Step 3, after the amplicon is subjected to enzyme digestion and fragmentation treatment, the ends are repaired and A is added, and the adapter is connected; Step 4: perform high-throughput sequencing.

3. The sample data analysis method according to claim 2, characterized in that: Sequencing was performed using the SE50 method.

4. The sample data analysis method according to claim 2, characterized in that: The BGI200 sequencing platform was used, and the adapter sequences are shown in SEQ ID NOs. 43, 47, 48, and 46.

5. The sample data analysis method according to claim 2, characterized in that: The sample is selected from alveolar lavage fluid, sputum, pleural effusion, swabs (oropharyngeal swabs, cheek swabs, etc.), blood sediment, pus, bile, renal lavage fluid, pericardial effusion, joint fluid, cerebrospinal fluid, whole blood, drainage fluid, puncture fluid, fresh tissue, and feces.